Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444268 · ClinicalTrials.gov registry record · Phase 1
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07444268: Recruiting Phase 1 study, sponsored by Sumitomo Pharma America.
NCT07444268 is a Phase 1 study that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07444268, a Phase 1 study, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
Primary Outcome
The percentage of dose excreted in urine
Interventions
- DRUG DSP-5336
- DRUG [14C]-DSP-5336
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What NCT07444268 shows while recruiting
NCT07444268 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which DSP-5336 is the first listed.
NCT07444268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07444268 about?
NCT07444268 is a clinical study titled "How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers". The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
What is the current status of trial NCT07444268?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-03-26. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07444268?
The interventions under investigation include: DSP-5336 (DRUG), [14C]-DSP-5336 (DRUG).
Who is sponsoring clinical trial NCT07444268?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07444268's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI